ICER posts draft scoping document for the assessment of treatments for cystic fibrosis

ICER

30 September 2019 - Document open to public comment until 21 October 2019.

The Institute for Clinical and Economic Review (ICER) has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value treatments for cystic fibrosis. ICER’s report will focus on elexacaftor/tezacaftor/ivacaftor (Vertex Pharmaceuticals). 

ICER also will examine any new data that has become available since its May 2018 review of three other CF treatments already approved by the FDA: tezacaftor/ivacaftor (Symdeko, Vertex), lumacaftor/ivacaftor (Orkambi, Vertex), and ivacaftor (Kalydeco, Vertex).

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder